A Phase II, Open-Label Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
Most Recent Events
- 23 Aug 2022 New trial record